Lucy Lu's Insider Trades & SAST Disclosures
Lucy Lu's most recent trade in Veru Inc was a trade of 30,000 Common Stock Option done . Disclosure was reported to the exchange on May 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lucy Lu.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 30,000 | 30,000 | - | - | Common Stock Option | |
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2025 | 1,422 | 17,535 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 13.35 per share. | 17 Apr 2025 | 179 | 6,396 (0%) | 0% | 13.4 | 2,390 | Common Stock |
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 37 | 16,112 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Natural Health Trends Corp. | Lucy Nduati | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 10,370 | 10,370 | - | - | Phantom Stock | |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.03 per share. | 21 Mar 2025 | 159 | 6,216 (0%) | 0% | 15.0 | 2,390 | Common Stock |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.03 per share. | 21 Mar 2025 | 159 | 6,216 (0%) | 0% | 15.0 | 2,390 | Common Stock |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.01 per share. | 11 Mar 2025 | 3,207 | 3,207 (0%) | 0% | 15.0 | 48,137 | Common Stock |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 144,196 | 239,716 (0%) | 0% | - | Class A Common Stock | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.87 per share. | 28 Feb 2025 | 69,648 | 170,068 (0%) | 0% | 13.9 | 966,018 | Class A Common Stock |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 93,000 | 93,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 46,500 | 79,170 | - | 0 | Common Stock | |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.42 per share. | 21 Feb 2025 | 155 | 6,057 (0%) | 0% | 15.4 | 2,390 | Common Stock |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 15.52 per share. | 24 Jan 2025 | 154 | 5,902 (0%) | 0% | 15.5 | 2,390 | Common Stock |
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 37 | 16,075 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 03 Jan 2025 | 2,957 | 32,670 | - | 1.3 | 3,965 | Common Stock |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 67,500 | 67,500 | - | - | Stock Option | |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 23,585 | 50,759 (0%) | 0% | - | Common Stock | |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2025 | 23,585 | 0 | - | - | Restricted Stock Unit | |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 21,552 | 21,552 | - | - | Restricted Stock Unit | |
| Fortress Biotech Inc | Lucy Lu | Director | 01 Jan 2025 | 49,383 | 61,273 (0%) | 0% | 0 | common stock, par value $0.001 | ||
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Payment of exercise price or tax liability using portion of securities received from the company at price $ 300.58 per share. | 15 Oct 2024 | 2,424 | 16,038 (0%) | 0% | 300.6 | 728,606 | Ordinary Shares, nominal value $0.000304635 per share |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 70,000 | 70,000 | - | - | Common Stock Option | |
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 9,980 | 13,306 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 5,156 | 18,462 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Willis Towers Watson Publi... | Lucy Clarke | President of Risk & Broking | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 3,326 | 3,326 (0%) | 0% | 0 | Ordinary Shares, nominal value $0.000304635 per share | |
| Hertz Global Holdings Inc.... | Lucy Clark Dougherty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 42,889 | 42,889 (0%) | 0% | 0 | Common Stock | |
| SAB Biotherapeutics Inc | Lucy To | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 20,000 | 20,000 | - | - | Common Stock Option | |
| Bath & Body Works Inc | Lucy O. Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,844 | 8,371 (0%) | 0% | 0 | Common Stock, $0.50 par value | |
| Pacific Biosciences of Cal... | Lucy Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 32,179 | 32,179 | - | - | Stock Option (right to buy) | |
| Pacific Biosciences of Cal... | Lucy Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 22,821 | 22,821 (0%) | 0% | 0 | Common Stock | |
| DoubleVerify Holdings Inc | Lucy Stamell Dobrin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,724 | 10,724 | - | - | Restricted Stock Units | |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2024 | 13,125 | 13,125 | - | - | Stock Option | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 30,627 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 30,627 | - | 0 | Common Stock | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 436,000 | 919,768 | - | - | Stock Appreciation Rights | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 37,566 | 113,666 (0%) | 0% | - | Class A Common Stock | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.31 per share. | 08 Mar 2024 | 18,146 | 95,520 (0%) | 0% | 13.3 | 241,523 | Class A Common Stock |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 3,018 | 3,018 (0%) | 0% | 0 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 31 Jan 2024 | 22,020 | 22,020 | - | - | Employee Stock Option (right to buy) | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 31 Jan 2024 | 3,891 | 20,768 (0%) | 0% | 0 | Common Stock | ||
| Polaris Inc | Clark Dougherty Lucy | SVP-Gen Counsel & Secretary | 31 Jan 2024 | 2,849 | 23,617 (0%) | 0% | - | Common Stock | ||
| Polaris Inc | Clark Dougherty Lucy | SVP-Gen Counsel & Secretary | 31 Jan 2024 | 1,403 | 22,214 (0%) | 0% | 90.0 | 126,214 | Common Stock | |
| Polaris Inc | Clark Dougherty Lucy | SVP-Gen Counsel & Secretary | 27 Jan 2024 | 1,537 | 16,877 (0%) | 0% | 91.4 | 140,436 | Common Stock | |
| Dyadic International Inc., DE | K. Patrick Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option | |
| Dyadic International Inc., DE | Lucy K. Patrick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 27,174 | 27,174 (0%) | 0% | - | Common Stock | |
| Dyadic International Inc., DE | Lucy K. Patrick | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 27,174 | 0 | - | - | Restricted Stock Unit | |
| Dyadic International Inc., DE | Lucy Patrick K. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 23,585 | 23,585 | - | - | Restricted Stock Unit | |
| Fortress Biotech Inc | Lu Lucy | Director | 01 Jan 2024 | 3,333 | 11,890 (0%) | 0% | 0 | COMMON STOCK, PAR VALUE $0.001 | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 33,594 | 18,414 (0%) | 0% | 134.2 | 4,507,979 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 19,237 | 37,651 (0%) | 0% | 113.0 | 2,173,973 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 19,237 | 0 | - | - | Employee Stock Option (right to buy) | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 13,069 | 6,534 | - | - | Employee Stock Options (right to buy) | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 13,069 | 50,720 (0%) | 0% | 117.4 | 1,533,909 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 6,581 | 57,301 (0%) | 0% | 111.3 | 732,597 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 6,581 | 13,160 | - | - | Employee Stock Options (right to buy) | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 4,106 | 53,195 (0%) | 0% | 137.9 | 566,135 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jul 2023 | 1,187 | 52,008 (0%) | 0% | 137.2 | 162,904 | Common Stock | |
| Columbia Financial, Inc | Lucy Sorrentini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 2,743 | 2,743 (0%) | 0% | 0 | Common Stock | |
| Bath & Body Works Inc | Lucy Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 3,572 | 4,527 (0%) | 0% | 0 | Common Stock, $0.50 par value | |
| Veru Inc | Lucy Lu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 10,000 | 10,000 | - | - | Common Stock Option | |
| Bath & Body Works Inc | Lucy Brady | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 955 | 955 (0%) | 0% | 0 | Common Stock, $0.50 par value | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 206,637 | 483,768 | - | - | Stock Appreciation Rights | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 40,701 | 95,760 (0%) | 0% | - | Class A Common Stock | |
| Sinclair Inc - Ordinary Sh... | Lucy A. Rutishauser | SVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.97 per share. | 02 Mar 2023 | 19,660 | 76,100 (0%) | 0% | 16.0 | 313,970 | Class A Common Stock |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Sale of securities on an exchange or to another person at price $ 460.33 per share. | 02 Mar 2023 | 553 | 4,144 (0%) | 0% | 460.3 | 254,562 | Common Stock |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 1,622 | 5,186 (0%) | 0% | 0 | Common Stock | |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 1,622 | 3,397 | - | - | Restricted Performance Stock Rights | |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 1,296 | 5,019 | - | - | Restricted Performance Stock Rights | |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Payment of exercise price or tax liability using portion of securities received from the company at price $ 465.35 per share. | 16 Feb 2023 | 489 | 4,697 (0%) | 0% | 465.3 | 227,556 | Common Stock |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 403 | 1,551 | - | - | Restricted Stock Rights | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 82,300 | 82,300 | - | - | Stock Option (right to buy) | |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2023 | 509 | 3,727 (0%) | 0% | 0 | Common Stock | |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2023 | 509 | 1,148 | - | - | Restricted Stock Rights | |
| Northrop Grumman Corp. | Lucy C Ryan | Corp VP, Communications | Payment of exercise price or tax liability using portion of securities received from the company at price $ 464.28 per share. | 13 Feb 2023 | 164 | 3,563 (0%) | 0% | 464.3 | 76,142 | Common Stock |
| Fortress Biotech Inc | Lucy Lu | Director | 10 Feb 2023 | 11,976 | 133,379 (0%) | 0% | 0.8 | 10,000 | COMMON STOCK, PAR VALUE $0.001 | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 01 Feb 2023 | 16,070 | 16,070 | - | - | Employee Stock Options (right to buy) | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 01 Feb 2023 | 6,224 | 21,478 (0%) | 0% | - | Common Stock | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 01 Feb 2023 | 3,064 | 18,414 (0%) | 0% | 117.8 | 360,878 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 01 Feb 2023 | 2,972 | 15,254 (0%) | 0% | 0 | Common Stock | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 31 Jan 2023 | 10,626 | 0 | - | - | Employee Stock Options (right to buy) | ||
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 31 Jan 2023 | 10,626 | 12,282 (0%) | 0% | 115 | 1,221,990 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 31 Jan 2023 | 10,626 | 22,908 (0%) | 0% | 94.5 | 1,004,582 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 31 Jan 2023 | 4,454 | 12,282 (0%) | 0% | 111 | 494,394 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jan 2023 | 4,193 | 18,613 (0%) | 0% | 107.2 | 449,406 | Common Stock | |
| Polaris Inc | Lucy Clark Dougherty | SVP-Gen Counsel & Secretary | 27 Jan 2023 | 1,877 | 16,736 (0%) | 0% | 107.2 | 201,177 | Common Stock | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 321,875 | 2,773,232 (3%) | 0% | - | Common Stock | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 321,875 | 0 | - | - | Restricted Stock Units | |
| Casa Systems Inc | Lucy Xie | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.26 per share. | 08 Jan 2023 | 272,545 | 2,629,437 (3%) | 0% | 3.3 | 889,859 | Common Stock |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 143,802 | 2,451,357 (2%) | 0% | - | Common Stock | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 143,802 | 0 | - | - | Restricted Stock Units | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 128,750 | 2,901,982 (3%) | 0% | - | Common Stock | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 128,750 | 0 | - | - | Restricted Stock Units | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 106,606 | 2,307,555 (2%) | 0% | - | Common Stock | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 106,606 | 0 | - | - | Restricted Stock Units | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 31,570 | 2,200,949 (2%) | 0% | - | Common Stock | |
| Casa Systems Inc | Lucy Xie | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2023 | 31,570 | 0 | - | - | Restricted Stock Units | |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 35,000 | 35,000 | - | - | Stock Option | |
| Dyadic International Inc., DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 27,174 | 27,174 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges